These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 15774576)
41. Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Sivasubramanian A; Chao G; Pressler HM; Wittrup KD; Gray JJ Structure; 2006 Mar; 14(3):401-14. PubMed ID: 16531225 [TBL] [Abstract][Full Text] [Related]
42. mAb806 binding to epidermal growth factor receptor: a computational study. Ng YZ; Kannan S; Lane DP; Fuentes G; Verma CS Proteins; 2015 Jan; 83(1):153-68. PubMed ID: 25370927 [TBL] [Abstract][Full Text] [Related]
43. Role of N-glycosylation in EGFR ectodomain ligand binding. Azimzadeh Irani M; Kannan S; Verma C Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782 [TBL] [Abstract][Full Text] [Related]
44. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. Gan HK; Walker F; Burgess AW; Rigopoulos A; Scott AM; Johns TG J Biol Chem; 2007 Feb; 282(5):2840-50. PubMed ID: 17092939 [TBL] [Abstract][Full Text] [Related]
45. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Scott AM; Lee FT; Tebbutt N; Herbertson R; Gill SS; Liu Z; Skrinos E; Murone C; Saunder TH; Chappell B; Papenfuss AT; Poon AM; Hopkins W; Smyth FE; MacGregor D; Cher LM; Jungbluth AA; Ritter G; Brechbiel MW; Murphy R; Burgess AW; Hoffman EW; Johns TG; Old LJ Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4071-6. PubMed ID: 17360479 [TBL] [Abstract][Full Text] [Related]
46. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. Gan HK; Lappas M; Cao DX; Cvrljevdic A; Scott AM; Johns TG J Cell Mol Med; 2009 Sep; 13(9B):3993-4001. PubMed ID: 19432811 [TBL] [Abstract][Full Text] [Related]
47. 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies. Garrido G; Sanchez B; Rodriguez HM; Lorenzano P; Alonso D; Fernandez LE Hybrid Hybridomics; 2004 Jun; 23(3):168-75. PubMed ID: 15312307 [TBL] [Abstract][Full Text] [Related]
48. Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor. Osaki T; Wang CX; Tachibana T; Azuma M; Kitamura M; Nakanishi T Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):418-22. PubMed ID: 26683181 [TBL] [Abstract][Full Text] [Related]
49. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Garrett TP; Burgess AW; Gan HK; Luwor RB; Cartwright G; Walker F; Orchard SG; Clayton AH; Nice EC; Rothacker J; Catimel B; Cavenee WK; Old LJ; Stockert E; Ritter G; Adams TE; Hoyne PA; Wittrup D; Chao G; Cochran JR; Luo C; Lou M; Huyton T; Xu Y; Fairlie WD; Yao S; Scott AM; Johns TG Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5082-7. PubMed ID: 19289842 [TBL] [Abstract][Full Text] [Related]
51. Differential immunoscreening identifies a glycosylation variant of the epidermal growth factor receptor in ME-180 cervical carcinoma cells. Hsu YT; Hou Q; Zhou H; Mohanty S; Litvinchuk A Hybridoma (Larchmt); 2005 Oct; 24(5):225-30. PubMed ID: 16225421 [TBL] [Abstract][Full Text] [Related]
52. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Mattoon D; Klein P; Lemmon MA; Lax I; Schlessinger J Proc Natl Acad Sci U S A; 2004 Jan; 101(4):923-8. PubMed ID: 14732693 [TBL] [Abstract][Full Text] [Related]
53. Identification and characterization of Ch806 mimotopes. Yang L; Jiang H; Shi B; Wang H; Li J; Wang H; Yao M; Li Z Cancer Immunol Immunother; 2010 Oct; 59(10):1481-7. PubMed ID: 20544195 [TBL] [Abstract][Full Text] [Related]
54. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Ohman L; Gedda L; Hesselager G; Larsson R; Nister M; Stigbrand T; Wester K; Carlsson J Tumour Biol; 2002; 23(2):61-9. PubMed ID: 12065843 [TBL] [Abstract][Full Text] [Related]
55. Antibody-induced inhibition of growth of egfr overexpressing tumors occurs in the absence of receptor down-regulation. Modjtahedi H; Dean C Int J Oncol; 1995 Oct; 7(4):783-8. PubMed ID: 21552904 [TBL] [Abstract][Full Text] [Related]
56. N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Kaszuba K; Grzybek M; Orłowski A; Danne R; Róg T; Simons K; Coskun Ü; Vattulainen I Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4334-9. PubMed ID: 25805821 [TBL] [Abstract][Full Text] [Related]
57. Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation. Ymer SI; Greenall SA; Cvrljevic A; Cao DX; Donoghue JF; Epa VC; Scott AM; Adams TE; Johns TG Cancers (Basel); 2011 Apr; 3(2):2032-49. PubMed ID: 24212795 [TBL] [Abstract][Full Text] [Related]
58. Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. Van Hal NL; Van Dongen GA; Ten Brink CB; Herron JN; Snow GB; Brakenhoff RH Cancer Immunol Immunother; 1997 Oct; 45(2):88-92. PubMed ID: 9390199 [TBL] [Abstract][Full Text] [Related]